The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
Open Access
- 22 January 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (2) , 81
Abstract
We investigated the comparative age-related efficacy of dimethyl fumarate (DMF) and natalizumab (NTZ) in clinical practice on multiple sclerosis (MS). Research in this area is lacking in the previous literature. In a three-year retrospective and clinical–paraclinical study, we compared 173 DMF patients and 94 NTZ patients with a similar average age (40 years) and disease duration (DD) (10 years). Expanded Disability Status Scale (EDSS) scores were higher in the NTZ group than in the DMF group at 3.5 vs. 2.5, respectively (p = 0.001). However, in both groups, age values correlated with DD (r = 0.42; p < 0.001), EDSS (r = 0.52; p < 0.001) and age at onset (r = 0.18; p < 0.001). Furthermore, age-adjusted Kaplan–Meier curves showed that NTZ-treated subjects maintained a 1.0–3.0 EDSS status score (p = 0.003) more frequently and a 3.5–7.0 score (p = 0.022) significantly less frequently compared with DMF-treated subjects. The EDSS percentage mean difference between NTZ and DMF groups was 81.6%, decreasing inversely with age (r = −0.34; p < 0.001). Finally, high EDSS score values were reached at the age of 39–40 years, regardless of their experimental group. We demonstrated age as a major contributor in disability and response to therapy in current management of MS. Thus, age should be considered in the risk/benefit evaluation in decision making for the disease modifying treatments in MS.Keywords
This publication has 23 references indexed in Scilit:
- Innate immunosenescence: Effect of aging on cells and receptors of the innate immune system in humansSeminars in Immunology, 2012
- Progressive multiple sclerosis: pathology and pathogenesisNature Reviews Neurology, 2012
- Age and disability accumulation in multiple sclerosisNeurology, 2011
- B cell immunosenescence: different features of naive and memory B cells in elderlyBiogerontology, 2011
- The Immunopathophysiology of Multiple SclerosisNeurologic Clinics, 2011
- A Gradient of neuronal loss and meningeal inflammation in multiple sclerosisAnnals of Neurology, 2010
- Evidence for a two-stage disability progression in multiple sclerosisBrain, 2010
- Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathologyBrain, 2006
- Age at disability milestones in multiple sclerosisBrain, 2006
- Disability, disease duration, and rehabilitation service needs in multiple sclerosis: Patient perspectivesArchives of Physical Medicine and Rehabilitation, 1986